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variance. AVP ¼ arginine vasopreTo the Editor: Plasma levels of the neurohormone arginine vaso-
pressin (AVP) are increased in patients with heart failure (HF),
and there is a direct relationship between a rise in AVP levels
and increased morbidity and mortality (1). Arginine vasopressin
activates a family of distinct G-protein–coupled receptors: V1A
receptors (V1A-R) in the heart, vasculature, and liver; and V2
receptors (V2-R) in the kidney. Activation of V2-Rs causes
reabsorption of free water, with excessive activation leading to
hyponatremia. The V2 antagonists increase serum levels of sodium
but do not have a salutary effect on clinical outcome in patients
with HF, and they increase serum levels of AVP (2). Recent
studies demonstrate that overexpression of the V1A-R in a mouse
model diminished cardiac function independent of an effect on
the vasculature (3). However, little is known about the regulation
of the V1A-R in the failing heart. Therefore, the present study was
undertaken to evaluate the expression of the V1A-R in failing and
nonfailing human hearts.
Human left ventricular (LV) myocardium was obtained from 25
subjects with end-stage HF undergoing heart transplant (19 men,
6 women, mean age 51.2  2.7 years) or from 8 organ donors
(1 man, 7 women, mean age 59.3  3.2 years) whose hearts were
unsuitable for donation owing to blood type, age, or size in-
compatibility. Nine of the transplant recipients had HF secondary to
ischemic cardiomyopathy. All had severe LV dysfunction: the mean
LV ejection fraction was 11.9  0.8%. At the time of surgery, 3
of the transplant recipients were receiving dobutamine alone, 11 wereo
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alysis with [125I]-p-AVP indicates a signiﬁcant increase in
ugh V1AR afﬁnity for ligand was not different between fail
se chain reaction reveals a signiﬁcant increase in AVPR1
, and data are presented as relative quantitation (RQ) wi
ssin.receiving milrinone alone, and 8 were receiving both. The nonfailing
hearts demonstrated normal LV function by echocardiography (LV
ejection fraction 60.4  2.2%). Tissue aliquots were removed from
the LV free wall, rapidly frozen in liquid nitrogen, and stored
at 70C (4). The Temple University Institutional Review Board
approved the study, and consent was obtained for all subjects.
Reverse-transcribed complementary deoxyribonucleic acid from
myocardial messenger ribonucleic acid (1 mg) was used to deter-
mine the expression of human V1A-R (AVPR1A) with ribosomal
protein S18 (RPS18) for normalization of gene expression data.
The ribonucleic acid was extracted with RNeasy Fibrous Tissue
Midi Kit (Qiagen, Valencia, California). The primers for AVPRIA
were F- 50-CTTGAAGGAGATGGCCACTAAA-30 and R- 50-
GTGATCGTGACGGCTTACAT-30. The primers for RPS18
were F- 50-CTTTGCCATCACTGCCATTAAG-30 and R- 50-
ATCACACGTTCCACCTCATC-30. The DDCT method
(Applied Biosystems, Foster City, California) was used to calculate
relative quantitation (RQ) values.
Membrane fractions for radioligand binding assays were pre-
pared as previously described (5). The protein concentration was
determined by the method of Lowry. The V1A-R levels were
measured by saturation of radioligand 125I-p-AVP (NE-
X310010UC, PerkinElmer, Waltham, Massachusetts) binding (kd
35 pmol/l for human recombinant V1A –R). Membrane prepara-
tions (approximately 40 mg protein) were incubated with
125I-p-AVP (4 to 300 pmol/l) in buffer (mmol/l: Tris 50,N
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vasopressin 1A receptor (V1AR) plasma membrane expression in failing hearts over
ing and nonfailing hearts (kd,) (B), unpaired t test with Welch’s correction for unequal
A expression in failing human hearts versus nonfailing human hearts. AVPR1A
th RQmin and RQmax as error bars, unpaired t test with Welch’s correction for unequal
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376ethylenediaminetetraacetic acid-5, 0.1% bovine serum albumin)
either alone or with 5 mmol/l of the V1A selective blocker SR49059.
Incubation was at 25C for 2 h in a volume of 100 ml, and steady-
state kinetics were achieved in speciﬁc binding. The reaction was
terminated with ice-cold incubation buffer and rapid vacuum
ﬁltration through glass ﬁber ﬁlters. Each ﬁlter was washed 3 with
7 ml of ice-cold 10 mmol/l Tris-hydrochloric acid plus 0.1% bovine
serum albumin. Radioactivity was determined in a Gamma counter.
All assays were performed in duplicate. Receptor density was
normalized to membrane protein. The dissociation constant (kd)
and the maximal number of binding sites (Bmax) for
125I-p-AVP
were determined by Scatchard analysis of saturation binding iso-
therms with Graphpad Prism (GraphPad, San Diego, California).
Nonspeciﬁc binding was 30% and was subtracted from total
binding. When using the radio-labeled antagonist speciﬁc for
V1A-R (kd 30 pmol for human recombinant V1A-R), all Scatchard
plots were linear, and the binding curves ﬁt a 1 binding site model.
As seen in Figure 1, the density of V1A-R was signiﬁcantly
increased in failing hearts when compared with nonfailing heart
control subjects without any change in the afﬁnity of the ligand for
the receptor. That the change in density was due to an increase in
receptor expression was supported by the fact that there was a
comparable increase in the levels of the messenger ribonucleic acid
encoding V1A-R (Fig. 1). This represents the ﬁrst report demon-
strating changes in V1A-R expression in HF. The majority of the
patients were receiving inotropic therapy, and therefore our ﬁndings
might not be generalizable to patients with less severe disease.
Interestingly, our ﬁndings are in contrast with the decrease in the
expression of b1-adrenergic and angiotensin type 1 receptors that
characterize the failing human heart (4). Further studies will be
required to better understand the molecular mechanisms responsible
for this difference as well as to determine whether these changes in
receptor density contribute to diminished cardiac function observed
in patients with end-stage HF and elevated the levels of AVP.Weizhong Zhu, MD, PhD
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1381–2.Letters to the Editor
Same-Day Discharge After
Percutaneous Coronary Intervention
Trial Sequential Analysis of Outcomes
In the comparison made between same-day discharge and routine
overnight observation by Brayton et al. (1), the best level of evi-
dence was that derived from randomized controlled trial (RCT)
studies. With regard to the composite outcome of death, myocar-
dial infarction, or target lesion revascularization, the analysis of
7 RCTs showed no signiﬁcant differences between the 2 ap-
proaches (pooled odds ratio: 0.90; 95% conﬁdence interval: 0.43 to
1.87; p ¼ 0.78). While this result supports the conclusion of no
proven difference, the main question is whether or not the available
data support a conclusion in terms of proof of no difference (or
proof of noninferiority) rather than the mere demonstration of no
proof of difference.
One problem in exploring these methodological questions is that
the degree of consensus on how noninferiority meta-analysis can be
conducted is still modest (2). On the other hand, the advantages of
trial sequential analysis (TSA) are being recognized increasingly
not only for handling questions of superiority (3,4) but also with
regard to those of noninferiority (3–5); in fact, TSA aims at clas-
sifying each meta-analysis into one of only 4 categories (superiority,
inferiority, futility/noninferiority, inconclusive result).
We applied TSA to the same 7 RCTs examined by Brayton et al.
(1). Our assumptions included 2-sided testing, type 1 error of 5%, and
a power of 80%. With respect to the above-mentioned composite
outcome, the intervention effect was set at a relative risk reduction
(RRR) of 50%or 33%.The expected absolute event rate in the controls
was 7.6% (i.e., the cumulative arithmetic rate in the control groups of
the 7RCTs).Themain result ofTSAwasexpressed through the graph
of a cumulative z-curve; the boundaries in this graph for concluding
superiority or inferiority or futility were determined according to the
O’Brien–Fleming alpha-spending function. All calculations were
carried out using a speciﬁc statistical software (User Manual for TSA,
TSA, Copenhagen Trial Unit 2011).
Our results are shown in Figure 1. The number of events
recorded in the RCTs proved to be insufﬁcient to construct the
boundaries of futility in both analyses; in addition, the statisti-
cal procedure incorporated only 6 RCTs because one trial
